Cite
MLA Citation
Simon Z. He et al.. “A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.” Leukemia & lymphoma, vol. 56, no. 5, n.d., pp. 1406–1415. http://access.bl.uk/ark:/81055/vdc_100025996432.0x000002